Context Therapeutics (NASDAQ:CNTX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11), Zacks reports.
Context Therapeutics Stock Down 6.7 %
Shares of NASDAQ CNTX traded down $0.14 during mid-day trading on Friday, hitting $1.95. The company had a trading volume of 339,093 shares, compared to its average volume of 295,287. The business's 50-day simple moving average is $2.09 and its 200 day simple moving average is $2.06. Context Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.75.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd.
Check Out Our Latest Stock Report on CNTX
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
